Investors
Pheon are backed by world-leading, specialist healthcare investors: Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies (RCT)
About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
For more information, please visit www.atlasventure.com
About Brandon Capital
Brandon Capital is Australasia’s leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialization.
Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of over 50 leading medical research institutes, investors, and government united by a single purpose: progressing the next generation of medical therapies and technology which improve health and save lives.
For more information, please visit www.brandoncapital.vc
About Forbion
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in 92 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fonds investments”. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
For more information, please visit www.forbion.com
About RCT
Research Corporation Technologies (RCT) is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. Founded in 1987, RCT continues a vision charted in 1912 to invest in technology that originates from universities and research institutions worldwide.
RCT has assets of more than $500 million to advance technology development through venture investment, partnerships and special licensing programs.
To support these programs, RCT has staff in its corporate office in Tucson, Arizona. RCT employs investment professionals with expertise in the life sciences, development of medical devices and therapeutics and financial management.
For more information, please visit www.rctech.com
